YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway

References

• WangYGuanGChengWARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXLBMC Cancer201818159929843637
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJEPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837
   PubMed Web of Science ®Google Scholar
• NishikawaRStandard therapy for glioblastoma – a review of where we areNeurolo Med Chir2010509713719
   PubMed Web of Science ®Google Scholar
• MessaoudiKClavreulALagarceFToward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomideDrug Discov Today201520789990525744176
   PubMed Web of Science ®Google Scholar
• SatoASunayamaJMatsudaKMEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axisStem Cells201129121942195121957016
   PubMed Web of Science ®Google Scholar
• ZhangJStevensMDBradshawTTemozolomide: mechanisms of action, repair and resistanceCurr Mol Pharmacol20125110211422122467
   PubMedGoogle Scholar
• GrekCLShengZNausCCSinWCGourdieRGGhatnekarGGNovel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeuticsCurr Opin Pharmacol201841798829803991
   PubMed Web of Science ®Google Scholar
• BargouRCJürchottKWagenerCNuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expressionNat Med1997344474509095180
   PubMed Web of Science ®Google Scholar
• LinZLuYMengQmiR372 promotes progression of liver cancer cells by upregulating erbB-2 through enhancement of YB-1Mol Ther Nucleic Acids20181149450729858084
   PubMedGoogle Scholar
• PerazzoliGPradosJOrtizRTemozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expressionPLoS One20151010e014013126447477
   PubMed Web of Science ®Google Scholar
• MantwillKNaumannUSeznecJYB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cellsJ Transl Med20131121624044901
   PubMed Web of Science ®Google Scholar
• Villalonga-PlanellsRColl-MuletLMartínez-SolerFActivation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiformePLoS One201164e1858821483692
   PubMed Web of Science ®Google Scholar
• JanouskovaHMaglottALegerDYIntegrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade gliomaEur J Cancer2012721434633470
   Google Scholar
• ToKFotovatiAReipasKMY-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistanceCancer Res20107072840285120332234
   PubMed Web of Science ®Google Scholar
• YamashitaTHigashiMMomoseSMorozumiMTamaruJINuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancerInt J Oncol201751257958628714514
   PubMed Web of Science ®Google Scholar
• ShurinMRCancer as an immune-mediated diseaseImmunotargets Ther201211627471681
   PubMedGoogle Scholar
• CinatlJSpeidelDHardcastleIMichaelisMResistance acquisition to MDM2 inhibitorsBiochem Soc Trans201442475275725109953
   PubMed Web of Science ®Google Scholar
• FengYWangLLiuXHuman corticotrophin releasing factor inhibits cell proliferation and promotes apoptosis through upregulation of tumor protein p53 in human gliomaOncol Lett20181568378838629805572
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEMasonWPEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
   PubMed Web of Science ®Google Scholar
• ZhangHLuoSZhangXSEECancer: a resource for somatic events in evolution of cancer genomeNucleic Acids Res201846D1D1018D102629069402
   PubMed Web of Science ®Google Scholar
• van RoeyenCRScurtFGBrandtSCold shock Y-box protein-1 proteolysis autoregulates its transcriptional activitiesCell Commun Signal20131116324103640
   PubMed Web of Science ®Google Scholar
• KohnoKIzumiHUchiumiTAshizukaMKuwanoMThe pleiotropic functions of the Y-box-binding protein, YB-1Bioessays200325769169812815724
   PubMed Web of Science ®Google Scholar
• BerquinIMPangBDziubinskiMLY-box-binding protein 1 confers EGF independence to human mammary epithelial cellsOncogene200524193177318615735691
   PubMed Web of Science ®Google Scholar
• ChenHZTsaiSYLeoneGEmerging roles of E2Fs in cancer: an exit from cell cycle controlNat Rev Cancer200991178579719851314
   PubMed Web of Science ®Google Scholar
• LashamAMoloneySHaleTThe Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressorJ Biol Chem200327837355163552312835324
   PubMed Web of Science ®Google Scholar
• BergmannSRoyer-PokoraBFietzeEYB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplificationCancer Res200565104078408715899797
   PubMed Web of Science ®Google Scholar
• ChenXTaiLGaoJA stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activationJ Control Release2015218293526428461
   PubMed Web of Science ®Google Scholar
• KimSSRaitAKimEA nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survivalACS Nano2014865494551424811110
   PubMed Web of Science ®Google Scholar
• ShangarySWangSSmall-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapyAnnu Rev Pharmacol Toxicol200949122324118834305
   PubMed Web of Science ®Google Scholar
• RennerGNouletFMercierMCExpression/activation of α5β1 integrin is linked to the β-catenin signaling pathway to drive migration in glioma cellsOncotarget2016738621946220727613837
   PubMedGoogle Scholar
• BloughMDBeauchampDCWestgateMRKellyJJCairncrossJGEffect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastomaJ Neurooncol201110211720593219
   PubMed Web of Science ®Google Scholar
• TovarCGravesBPackmanKMDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsCancer Res20137382587259723400593
   PubMed Web of Science ®Google Scholar
• Yang-HartwichYSoterasMGLinZPp53 protein aggregation promotes platinum resistance in ovarian cancerOncogene201534273605361625263447
   PubMed Web of Science ®Google Scholar
• KnappskogSLønningPEP53 and its molecular basis to chemoresistance in breast cancerExpert Opin Ther Targets2012161S23S3022313396
   PubMed Web of Science ®Google Scholar
• ZauliGVoltanRBoscoRDasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathwayClin Cancer Res201117476277021106726
   PubMed Web of Science ®Google Scholar
• InoueKFryEAFrazierDPTranscription factors that interact with p53 and Mdm2Int J Cancer201613871577158526132471
   PubMed Web of Science ®Google Scholar